CARGO Therapeutics, Inc. Board of Directors

CARGO Therapeutics, Inc., a clinical-stage biotechnology company, develops chimeric antigen receptor (CAR) T-cell therapies for cancer patients. The company's lead program is CRG-022, an autologous CD22 CAR T-cell product candidate designed to address resistance mechanisms by targeting CD22, an alternate tumor antigen that is expressed in B-cell malignancies. It also develops CRG-023, a tri-specific CAR T product candidate that targets tumor cells with three B-cell antigen targets. The company was formerly known as Syncopation Life Sciences, Inc. and changed its name to CARGO Therapeutics, Inc. in September 2022. CARGO Therapeutics, Inc. was incorporated in 2019 and is headquartered in San Mateo, California.

Ms. Gina Chapman

Ms. Gina Chapman

President, CEO & Director

Dr. Michael Ports Ph.D.

Dr. Michael Ports Ph.D.

Chief Scientific Officer

Dr. Robbie Majzner M.D.

Dr. Robbie Majzner M.D.

Co-Founder & Scientific Advisory Board Member

Dr. Shishir Gadam Ph.D.

Dr. Shishir Gadam Ph.D.

Chief Technical Officer

Mr. Faisal Shawwa M.B.A.

Mr. Faisal Shawwa M.B.A.

Senior Vice President of Finance & Accounting

Dr. Crystal L. Mackall M.D.

Dr. Crystal L. Mackall M.D.

Co-Founder & Scientific Advisory Board Chair

Mr. Anup Radhakrishnan

Mr. Anup Radhakrishnan

CFO, Secretary & COO

Leaving Board of Directors Review Your about to visit the following url Invalid URL

Loading...
Comments


Comment created.